

Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333

E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au

13 March 2025

The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000

(2 pages by email)

Dear Madam

UPDATE ON RIGHTS ISSUE TIMETABLE ASX: BITR

Biotron Limited (**ASX:BIT**) (**Biotron** or **the Company**) refers to rights issue announced to the ASX on 28 February 2025 and for which the Company lodged a prospectus with ASIC on 3 March 2025 (**Rights Issue**).

Following queries by ASIC and ASX, on 12 March 2025 the Company lodged a replacement prospectus with ASIC and announced to the ASX that day. Following is an updated timetable for the Rights Issue:

Prospectus with Entitlement and Acceptance Form sent to Eligible Shareholders	18 March 2025
Offer opens for receipt of Applications	18 March 2025
Rights trading ends at close of trading	25 March 2025
Unless otherwise determined by ASX, new shares quoted on a deferred settlement basis from market open.	26 March 2025
Latest date to extend the Rights Issue	27 March 2025
Closing date for acceptances	5pm AEDT 1 April 2025
Announce results of the Rights Issue	8 April 2025
Issue of New Shares	8 April 2025
Normal trading of New Shares expected to commence	9 April 2025
Dispatch of shareholding statements	10 April 2025
Last date to issue Shortfall Shares	1 July 2025

Note: The Directors may extend the Closing Date by giving at least 3 Business Days' notice to ASX prior to the Closing Date, subject to such date being no later than 3 months after the date of the Prospectus. As such the date the New Shares are expected to commence trading on ASX may vary.

Eligible Shareholders may take up shortfall in addition to their entitlements under the Rights Issue. Applications for securities under the Rights Issue can be made via BPAY® by following the instructions set out in the personalised Entitlement and Acceptance Form that will be sent to Eligible Shareholders with the prospectus. Persons should consider the prospectus in deciding whether to acquire securities under the Rights Issue.

For more information please contact:

Enquiries:

Dr Michelle Miller Managing Director +61-(0) 41231 3329 Peter Nightingale Company Secretary +(612) 9300 3344

This announcement has been authorised for release to the market by the Managing Director.

Yours sincerely

Peter J. Nightingale Company Secretary

pjn12558